Market-Moving News for July 9th
$JNVR
$SNGX
$WENA
Finance: Consumer Services
Finance
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - Janover Inc. (0001805526) (Issuer)
424B5 - SOLIGENIX, INC. (0000812796) (Filer)
8-K - SOLIGENIX, INC. (0000812796) (Filer)
8-K - SOLIGENIX, INC. (0000812796) (Filer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below. Dear Friends and Shareholders, I would like to start by thanking you for your continued support, and by wishing you and your families a Happy New Year. With 2026 being an imp
Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest potential durability of response for maintenance therapyPRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers As
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F
BOCA RATON, FL, April 23, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corporation (NASDAQ:JNVR) (the "Company") today announced the appointment of Fei "John" Han as Chief Financial Officer, as well as Dan Kang ("DK") as Head of Investor Relations. The new appointments underscore the Company's commitment to building a world-class financial and investor relations function as it scales its crypto-forward treasury strategy. Han brings over 15 years of experience across traditional finance and crypto, with a track record of leadership at some of the crypto industry's most recognized institutions. Most recently, he served as CFO at blockchain-company Provable, and prior to that, held multiple sen
BOCA RATON, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Janover Inc. (NASDAQ:JNVR) ("Janover" or the "Company"), today announced that it will host a live X Spaces conversation on Friday, April 18th, 2025, at 2:30 p.m. Eastern Time, featuring members of its senior leadership team. The discussion will include: Joseph Onorati, Chairman and Chief Executive OfficerParker White, Chief Operating Officer and Chief Investment OfficerDan Kang, Head of Investor Relations The conversation will focus on NAV Premiums of crypto treasury vehicles, including structural considerations and recent market activity. To join the event, visit: https://x.com/i/spaces/1vOxwXpRObMKB/. The Company does not intend to
BOCA RATON, FL, April 07, 2025 (GLOBE NEWSWIRE) -- Janover, Inc. (NASDAQ:JNVR) (the "Company") announced today that it had raised approximately $42 million in an offering of convertible notes and warrants from Pantera Capital, Kraken, Arrington Capital, Protagonist, The Norstar Group, Third Party Ventures, Trammell Venture Partners, and 11 angel investors. The notes were sold in a private offering under Section 4(a)(2) under the Securities Act of 1933, as amended (the "Securities Act") and Regulation D promulgated thereunder. The aggregate principal amount of the convertible notes sold in the offering was approximately $42 million, which are convertible into the Company's common stock, pa
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th